Evista review

Evista, which is generically prescribed as raloxifene, is commonly used to treat or prevent osteoporosis in post menopausal women. Evista alters the bone mass and breakdown cycles in the body. While tests are still pending, Evista seems to have a very low or non-existent potential for increasing the risk of uterine or breast cancer in post menopausal women.

Evista is not appropriate for everyone. A thorough medical history should be assessed prior to prescribing this medication. Patients with a medical history which includes increased triglycerides, blood clots, stroke, cancer, or liver disease may not be able to take Evista or may require careful monitoring while undergoing drug therapy with this medication, depending on the condition and the severity of the condition. The American Food and Drug Administration rated Evista as a pregnancy risk category X. This medication has been proven to cause harm or birth defects in unborn babies. It has yet to be determined whether or not Evista passes through the mother’s breast milk and affects a nursing baby. The prescribing physician should avoid prescribing this medication to women who are pregnant, nursing, or are likely to become pregnant.

There is a risk of side effects associated with Evista, some of which are severe. A patient who is experiencing a serious side effect or an allergic reaction should seek immediate emergency medical attention. An allergic reaction will present with side effects such as facial swelling, including swelling of the lips, mouth, throat, or tongue, hives, and difficulty breathing. Other serious side effects which require immediate emergency medical attention include symptoms such as changes in vision, sharp pain in the legs, coughing up blood, swelling of the legs, sudden chest pain, or unexplained vaginal bleeding.

Less serious side effects typically do not require emergency medical attention but should be reported to the prescribing physician. Patients should be encouraged to report all side effects. Less serious side effects include symptoms such as hot flashes, sweating, weight gain, muscle aches, leg cramps, or a skin rash. Less serious side effects can often be reduced to a tolerable level by reducing the dosage of Evista.

Evista should be taken exactly as it has been prescribed by the physician. If the patient misses a dose, the dose should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to avoid the potential for an overdose. The patient should never take a double dose of this medication. If an overdose is suspected, the patient should seek immediate emergency medical attention. An overdose will present with symptoms such as possible severe muscle cramping, severe pain in the legs, vaginal bleeding or bloody discharge, confusion, or other symptoms.

There is a potential risk of negative drug interactions associated with Evista. A thorough medical history should be understood prior to prescribing this medication. Patients should be urged to inquire with the prescribing physician before taking any new medications, including over the counter medications and herbal remedies. Medications with a known negative drug interactions with Evista include cholestyramine, blood thinners, or estrogen or progesterone medication such as birth control pills. Evista may require being suspended in the event of a surgical procedure or during any time of extended bed rest.

Evista has the following structural formula:

Chemical structure of evista

 Molecular formula of evista is C28H27NO4S
 Chemical IUPAC Name is [6-hydroxy-2-(4-hydroxyphenyl)-benzothiophen-3-yl]- [4-[2-(1-piperidyl)ethoxy]phenyl]-methanone
 Molecular weight is 473.584 g/mol
 Evista available : 60mg tablets

Generic name: Raloxifene

Brand name(s): Keoxifene, Raloxifeno, Raloxifenum

  Your Evista review